Immunocore CFO Tries Zero‑Cost Bets on Future Share Gains, Boosting Insider Confidence in Rising Valuation
Insider buying by Immunocore’s CFO and execs signals confidence that the biotech’s stock is undervalued, hinting at upside as the pipeline advances.
4 minutes to read